Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push

Go back to Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push

Morgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea

January 5, 2023 4:09 PM EST

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "We expect the first interim analysis from Moderna's Ph3 RSV vaccine study in the near-term. We believe efficacy and safety in-between... More